C. diff is a leading cause of infectious diarrhea in adults 65 and older that can result in severe illness and recurrent symptoms. Learn about Pfizer’s new vaccine study which may help to protect against C. diff infection.
C. difficile (C. diff) is the leading cause of healthcare-related infectious diarrhea in the United States. People 65 or older are more likely to get a C. diff infection than other age groups. In severe cases, it can cause damage to the colon and may become life-threatening. Pfizer is working to develop a potential vaccine that could help protect those at greatest risk for C. diff infection.
About the study
The goal of this study is to understand how adults 65 and older respond to different dosing schedules and formulations of the study vaccine to see which may offer the best possible defense against C. diff infection.
Who can participate?
This research study is enrolling adults who:
- Are at least 65 years old
- Have not previously been diagnosed with a C. diff infection or received a C. diff vaccine
- Do not have any serious medical conditions such as advanced cancer, severe COPD, congestive heart failure, kidney failure, or cirrhosis
There will be other study requirements that the study team will discuss with you.
Participation could last a little over four years and includes up to 11 study visits.
All participants will receive two or three doses of the study vaccine (one of two formulations).
There is no cost to participate, and compensation will be provided.
Ready to learn more?
Contact the study team: 786-772-0510
